tetano
Editor, Senior Moderator
Immune Targeting Systems Limited ("ITS"), an emerging leader in the development of vaccines that promote T-cell responses against viruses and cancers, today announces compelling data from two Phase I clinical trials of FlunisynTM, the Company's lead vaccine programme which elicits potent immune responses against multiple strains of influenza-A virus. ITS also announces the appointments of Dr. Benjamin Chen, Executive Chairman and Dr. Kevin FitzGerald, Chief Operating Officer, to support the Company as it moves towards commercialisation of its products and technologies.
The first Phase I trial showed that FlunisynTM generated statistically significant cell-mediated immune responses to the vaccine and was safe and well tolerated in vaccinated groups compared to placebo. The trial was a randomised, double-blind, placebo-controlled, escalating dose study in 48 healthy adult volunteers.
The second trial was a randomised, double blind study to compare the immunogenicity of FlunisynTM, alone or with an undisclosed adjuvant, in 48 healthy adult volunteers. Both formulations generated strong cell-mediated immunity but with the adjuvant formulation generating enhanced responses.
..
http://www.news-medical.net/news/20...-against-multiple-strains-of-influenza-A.aspx
The first Phase I trial showed that FlunisynTM generated statistically significant cell-mediated immune responses to the vaccine and was safe and well tolerated in vaccinated groups compared to placebo. The trial was a randomised, double-blind, placebo-controlled, escalating dose study in 48 healthy adult volunteers.
The second trial was a randomised, double blind study to compare the immunogenicity of FlunisynTM, alone or with an undisclosed adjuvant, in 48 healthy adult volunteers. Both formulations generated strong cell-mediated immunity but with the adjuvant formulation generating enhanced responses.
..
http://www.news-medical.net/news/20...-against-multiple-strains-of-influenza-A.aspx